Yiting Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yiting Zhou has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Aili Wang
A Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases , Medical College of Soochow University , Suzhou , China
1 shared publicationChang Chen
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China
1 shared publicationChongke Zhong
A Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases , Medical College of Soochow University , Suzhou , China
1 shared publicationDonglai Chen
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China
1 shared publicationFeng Li
Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publicationGuangli Wang
A Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases , Medical College of Soochow University , Suzhou , China
1 shared publication
Latest Publications
- 4 September 2023
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (3) , 665-677
Multilevel chitosan–gelatin particles loaded with P4HA1 siRNA suppress glioma development
It has been reported that prolyl 4-hydroxylase subunit alpha 1 (P4HA1) promoted tumor growth and metastasis of glioma; thus, targeting P4HA1 may be a promising therapeutic strategy against glioma. In consideration of the instability of siRNA in vivo, the chitosan-gelatin microspheres loaded with P4HA1 siRNA (P4HA1 siRNA@CGM) were employed. Firstly, the gel electrophoresis and hemolytic test were performed to assess the stability and blood compatibility of P4HA1 siRNA@CGM. Then, methyl thiazolyl tetrazolium (MTT), cell colony formation, Transwell assay, wound healing assay, gliosphere formation, tube formation, and Western blot were performed to assess the effects of P4HA1 siRNA@CGM on the biological functions of glioma. Finally, 125I-labeled P4HA1 siRNA@CGM was injected into the xenograft mice, radionuclide imaging was recorded, Ki67 and terminal deoxynucleoitidyl transferase-mediated nick end labeling (TUNEL) staining was performed to assess the effects of P4HA1 siRNA@CGM on tumor growth and apoptosis of glioma in vivo. The results showed that P4HA1 siRNA and P4HA1 siRNA@CGM not only markedly inhibited the proliferation, metastasis, gliosphere formation, and the protein levels of interstitial markers (N-cadherin and vimentin) and the transcription factors of epithelial-mesenchymal transition (EMT) (Snail, Slug, and Twist1) in glioma cells, but also inhibited the tube formation in human brain microvascular endothelial cells (HBMECs), and P4HA1 siRNA@CGM exhibited the better inhibitory effects than P4HA1 siRNA. Above results suggested the feasibility of P4HA1 siRNA@CGM in the clinical treatment of glioma.
- 4 September 2023
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (3) , 665-677
Multilevel chitosan–gelatin particles loaded with P4HA1 siRNA suppress glioma development
It has been reported that prolyl 4-hydroxylase subunit alpha 1 (P4HA1) promoted tumor growth and metastasis of glioma; thus, targeting P4HA1 may be a promising therapeutic strategy against glioma. In consideration of the instability of siRNA in vivo, the chitosan-gelatin microspheres loaded with P4HA1 siRNA (P4HA1 siRNA@CGM) were employed. Firstly, the gel electrophoresis and hemolytic test were performed to assess the stability and blood compatibility of P4HA1 siRNA@CGM. Then, methyl thiazolyl tetrazolium (MTT), cell colony formation, Transwell assay, wound healing assay, gliosphere formation, tube formation, and Western blot were performed to assess the effects of P4HA1 siRNA@CGM on the biological functions of glioma. Finally, 125I-labeled P4HA1 siRNA@CGM was injected into the xenograft mice, radionuclide imaging was recorded, Ki67 and terminal deoxynucleoitidyl transferase-mediated nick end labeling (TUNEL) staining was performed to assess the effects of P4HA1 siRNA@CGM on tumor growth and apoptosis of glioma in vivo. The results showed that P4HA1 siRNA and P4HA1 siRNA@CGM not only markedly inhibited the proliferation, metastasis, gliosphere formation, and the protein levels of interstitial markers (N-cadherin and vimentin) and the transcription factors of epithelial-mesenchymal transition (EMT) (Snail, Slug, and Twist1) in glioma cells, but also inhibited the tube formation in human brain microvascular endothelial cells (HBMECs), and P4HA1 siRNA@CGM exhibited the better inhibitory effects than P4HA1 siRNA. Above results suggested the feasibility of P4HA1 siRNA@CGM in the clinical treatment of glioma.
- 3 May 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (8) , 1473-1478
Coexistence effect of hypertension and angiotensin II on the risk of coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China
Objective: To investigate the coexistence of hypertension and angiotensin II on the risk of coronary heart disease based on a prospective study in an Inner Mongolian population of China. Methods: The participants were categorized into four subgroups according to hypertension status and median of angiotensin II level. Incident coronary heart disease (CHD) was defined as study outcome. A cox proportional hazard model was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) of CHD across the four subgroups after adjusting for important confounding factors. Results: During average 9.2 years of follow-up, a total of 75 incident CHD cases were observed. The cumulative incidence rates of CHD among normotensives with angiotensin II ≤49 pg/mL, normotensives with angiotensin II >49 pg/mL, hypertensives with angiotensin II ≤49 pg/mL and hypertensives with angiotensin II >49 pg/mL were 1.76%, 1.50%, 4.71% and 5.62%, respectively (log-rank test, P < 0.001). Compared to the normotensives, the multivariable adjusted HRs (95% CI) of CHD with hypertensives and Ang II >49 pg/mL were 2.43(1.41-4.17) and 1.30(0.81-2.07), respectively. Furthermore, compared to normotensives with angiotensin II ≤49 pg/mL, the multivariate-adjusted HRs (95% CIs) of CHD for normotensives with angiotensin II >49 pg/mL, hypertensives with Angiotensin II ≤49 pg/mL and hypertensives with angiotensin II >49 pg/mL were 1.33(0.60-2.91), 2.35 (1.16-4.76) and 3.00(1.52-5.92), respectively (P for trend ). The hypertensives with angiotensin II >49 pg/mL were at the highest risk of CHD. Conclusions: Hypertension not angiotensin II was an independent risk factor for incident CHD, but coexistence of both hypertension and high angiotensin II level further increased risk of incident CHD among the Inner Mongolians.
- 3 May 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (8) , 1473-1478
Coexistence effect of hypertension and angiotensin II on the risk of coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China
Objective: To investigate the coexistence of hypertension and angiotensin II on the risk of coronary heart disease based on a prospective study in an Inner Mongolian population of China. Methods: The participants were categorized into four subgroups according to hypertension status and median of angiotensin II level. Incident coronary heart disease (CHD) was defined as study outcome. A cox proportional hazard model was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) of CHD across the four subgroups after adjusting for important confounding factors. Results: During average 9.2 years of follow-up, a total of 75 incident CHD cases were observed. The cumulative incidence rates of CHD among normotensives with angiotensin II ≤49 pg/mL, normotensives with angiotensin II >49 pg/mL, hypertensives with angiotensin II ≤49 pg/mL and hypertensives with angiotensin II >49 pg/mL were 1.76%, 1.50%, 4.71% and 5.62%, respectively (log-rank test, P < 0.001). Compared to the normotensives, the multivariable adjusted HRs (95% CI) of CHD with hypertensives and Ang II >49 pg/mL were 2.43(1.41-4.17) and 1.30(0.81-2.07), respectively. Furthermore, compared to normotensives with angiotensin II ≤49 pg/mL, the multivariate-adjusted HRs (95% CIs) of CHD for normotensives with angiotensin II >49 pg/mL, hypertensives with Angiotensin II ≤49 pg/mL and hypertensives with angiotensin II >49 pg/mL were 1.33(0.60-2.91), 2.35 (1.16-4.76) and 3.00(1.52-5.92), respectively (P for trend ). The hypertensives with angiotensin II >49 pg/mL were at the highest risk of CHD. Conclusions: Hypertension not angiotensin II was an independent risk factor for incident CHD, but coexistence of both hypertension and high angiotensin II level further increased risk of incident CHD among the Inner Mongolians.
- 1 October 2018
- Published by Elsevier in Lung Cancer
- Vol. 124, 211-218
Relationship between MTA1 and spread through air space and their joint influence on prognosis of patients with stage I-III lung adenocarcinoma
- 1 October 2018
- Published by Elsevier in Lung Cancer
- Vol. 124, 211-218
Relationship between MTA1 and spread through air space and their joint influence on prognosis of patients with stage I-III lung adenocarcinoma